Created with Sketch.
64 minutes | a day ago
#39: All You Need to Know About the Novel €95.5 Billion Horizon Europe Programme...
This podcast episode will discuss the EU’s next framework program for research and innovation, Horizon Europe, and the exciting opportunities this program offers businesses, scientists, and investors. With the launch of the Horizon Europe program just weeks away, we will share insight into the program's novelties, where to start, and tips on how to be successful. The Podcast Host, guests Kimberly Cornfield and Michael Browne will discuss questions like:What is new in Horizon Europe? The European Innovation Council, Missions and Clusters – all you need to knowFunding for DeepTech? The opportunities for high-risk/high gain and interdisciplinary research and innovation collaborationWhere, when, and how to apply for Horizon Europe funding? – tips from the expertsWe shall address all these questions and discuss the latest priorities in EU research and innovation funding and the importance of collaboration.Our guests in this episode:Kimberly Cornfield is Head of European Research and Innovation at University College London (UCL), one of the top-performing universities under the EU’s Horizon 2020 program, having secured ca. €400 million over the last seven years to support its research and innovation activities. To support UCL in upholding its place as one of the leading universities in the next EU research and innovation program, Horizon Europe, and achieving its impact objectives, Kimberly and her team connect scientists and business around EU collaborative funding opportunities and offer a suite of support services to improve the chances of success in obtaining funding and achieving their impact objectives.Michael Browne is Director and Co-founder at Crowdhelix - an Open Innovation Platform that forges links between an international network of excellent researchers and innovating companies to help deliver pioneering collaborative projects. Michael has worked in the European Research & Innovation space for more than 15 years and is a recognized expert in Framework Programme funding.Host:Christian SoschnerLink to the Video of the Recording:Youtube VideoBe part of our Network:Subscribe here: LinkSupport the show (https://lsg2g.substack.com/subscribe?)
88 minutes | 22 days ago
#38: Dusica Lukac - The Magic of Corporate Finance
In this podcast episode, we will discuss several different forms of growth and scaling up companies. In the era of the fast-growing unicorns and skyrocketing valuations, we try to disassemble the growth path and see what a founder can do to benefit most of these options. How to decide if an organic or buy&build model is the right one for me? Are mergers & acquisitions play-field only for the very mature companies? When is the time to start with bolt-on acquisitions? Is fast growth really possible in only an organic way? We shall address all these questions, look into the latest M&A trends of 2020 and 2021, shed a light on the life science industry, and discuss several real-life cases of buy&build growth models. As we are excited about the next podcast episode let us just say ‘Hopin' our podcast episode for more. Dusica Lukac holds an Executive MBA from Carlson Business School, Minnesota, the US and Wirtschaft Universitaet Wien, Vienna, Austria: Entrepreneurial Specialization and Fintech Law and Regulations courses Duke University, US; Private Equity and Venture Capital course Bocconi, Italy.Traveled to 78 countries, multilingual, fascinated with financial innovation, watercolor painter.Link to the Video of the Recording:YouTubeSpeaker:Astrid WoollardChristian SoschnerDusica H. LukacOrganizations:CS Life Science InvestDL Capital Partners LtdXenoVCBe part of our Network:Subscribe here: LinkSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
67 minutes | 2 months ago
#37: Peer-to-Peer Energy Trading
In this podcast episode, we will discuss how blockchain technology is utilized in the energy sector beyond the well-known utility of a payments system, her experiences in entrepreneurship and innovation, including start-up life in Berlin.Ana Trbovich is the Grid Singularity co-founder & COO and Vice-Chair of the Energy Web Foundation. She serves on UNECE Carbon Neutrality and DENA SET Hub Advisory Boards, and previously acted as an independent board member at the European Institute for Innovation and Technology (EIT), Axa, and the Belgrade Philharmonic, among others. She teaches Entrepreneurship at FEFA, a leading business school in Belgrade, Serbia, where she also served as Dean from 2012 to 2015. She has consulted on good governance, competitiveness, and innovation policy for international organizations, including the EU and the World Bank.Link to the Video of the Recording:YouTubeSpeaker:Ana TrbovichAstrid WoollardChristian SoschnerOrganizations:CS Life Science InvestGrid SingularityScytale VenturesBe part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gThe LSG2G Partners Experts in Life ScienceSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
47 minutes | 2 months ago
#36: Secrets of Life Science Investments - An Introduction to Hadean Ventures
It was great fun to talk with Walter Stockinger, Co-Founder of Hadean Ventures, about the topic of Life Science Investments.We covered the following questions:How do Venture Funds operate?What do you need to know about approaching VCs?What is the purpose of a VC?Why are exits necessary for VCs?And what exit strategies are relevant?Why do VCs raise money, and from whom?Use the opportunity to get your answer directly from a VC.Link to the Video of the Recording:YouTubeSpeaker:Astrid WoollardChristian SoschnerWalter StockingerOrganizations:CS Life Science InvestHadean VenturesScytale VenturesBe part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
124 minutes | 3 months ago
#35: Why You Don’t Need to Quit Your Job to Be an Entrepreneur
This one is an episode for the go-getters and never-giveupers.Astrid and Christian had great fun talking with Essa Saulat, Chief Growth Officer of the Austrian digital health company Symptoma.Essa is a seasoned entrepreneur and helped many start-ups getting off the ground.In this episode, he shares his life story of overcoming adversity, keeping moving forward relentlessly, and ultimately changing his world and the worlds of many people he met in his life for the better.He shares in unambiguous words the most important question every entrepreneur needs to confront frequently.When you look at the most successful founders and companies globally, they all have clarity and a strong answer to this key question of entrepreneurship.Enjoy the show.Link to the Video of the Recording:YouTubeSpeaker:Astrid WoollardChristian SoschnerEssa SaulatOrganizations:CS Life Science InvestScytale VenturesSymptomaBe part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
68 minutes | 3 months ago
#34: Deal Structuring With the Pharma Industry - From the Investors Perspective
Drug Development is a challenging process. It needs profound basic research, translating scientific results into products and moving them towards the market.Making things more challenging deal structuring is also a b2b business, which means selling products to the pharma industry that completes the product development and brings therapeutics to patients.How does structuring deals with the pharma industry really work to sign one of those multi-billion dollar contracts?Sascha Bucher is a Venture Capital expert with tremendous experience in deal structuring with the pharmaceutical industry.In his career at renowned venture funds and companies like Roivant Sciences, Roche, or UBS, he completed transactions worth more than 10 billion dollars.To give life science entrepreneurs access to the expertise, network, and funding, he and his team are in the process of founding Forty51 Ventures - a novel venture fund dedicated to closing the Life Science Valley of Death in Central Europe.Join our conversation and learn more about how to negotiate with the pharmaceutical industry.Gain more insights into VCs' daily business life with a particular focus on building relationships with BD, R&D, and C-suite executives in the industry.Link to the Video of the Recording:YouTubeSpeaker:Astrid WoollardChristian SoschnerSascha BucherOrganizations:CS Life Science InvestForty51 VenturesScytale VenturesBe part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
86 minutes | 3 months ago
#33: Bridging the Biotech Valley of Death: From Patient-Owned Therapeutics to Modular Drug Development.
For more than 10 years the blockchain technology has shaped our economy. The background technology is mostly invisible for average users like me.On the front end, cryptocurrency has hit the news. I remember well the highs of Bitcoin in 2017. And recently, Bitcoin is rising again.But, and this is something I want to learn, what applications do exist that can improve the life science industries? Is there something else in the background that will help us solve the problems we have in drug development, medical devices, diagnostics, and digital health?These and many more questions will be answered by the experts Paul Kohlhaas and Astrid Woollard.Join us on this Life Science specific Blockchain update.Link to the Video of the Recording:YouTubeDo you prefer reading? Here is your Transcript ready for purchase in the LSG2G Etsy Shop.Speaker:Astrid WoollardChristian SoschnerPaul KohlhaasOrganizations:CS Life Science InvestMolecule.to Scytale VenturesBe part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gThe LSG2G Partners Experts in Life ScienceSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
100 minutes | 4 months ago
#32: Tax & Funding Update 2021 - Tech in Austria – Ask the Tax Experts of KPMG Austria
A new year brings new tax rules.Astrid Woollard and Christian Soschner asked the Tax Experts of KPMG Austria to give an update on the newest regulations in Austria.We also had a chance to talk about tax advisors and auditors' roles in the start-up economy.Listen to this episode to learn what's new and when to consult advisors.If you have questions after listening to the episode, reach out to Michael and Oliver.For the videophile:The Video to the PodcastResources mentioned in the podcast:Research Premium and its role in FundraisingGovernment and institution measures in response to COVID-19COVID-19 Tax Info (in German)Folge #099: Tax Hacks & Fun Stuff aus der Start-up-Beratungspraxis (in German)Speaker:Astrid Woollard Christian Soschner Michael KlewanOliver MavherOrganizations:CS Life Science Invest KPMG AustriaScytale VenturesShow Notes:00:11:27 Home Office and Taxation00:14:34 Funding and SMEs00:17:44 Solvency and Zombie Companies00:20:54 Cryptocurrency00:24:41 The Role of Tax Consultants and Auditors in Start-Up Companies00:31:58 AI in Bookkeeping00:36:00 Secrets of Auditing in the Start-Up World00:44:12 Wirecard and Auditing00:54:40 Tax Deadlines and Tax Breaks in 202101:04:14 Research Premium and SAAS01:26:17 Critical Deadlines in 202101:29:00 Tax Loss Carry Backwards01:34:00 New VC Fund for Start-Ups in Austria01:38:00 Invitation to Reach Out to Michael and Oliver.Be part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gThe LSG2G Partners Experts in Life ScienceSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
183 minutes | 4 months ago
#31: This was 2020 - A Year in Review
What was hot and what not - in Blockchain and Life Science and other Tech Areas the speakers love.Join Astrid Woollard, Christian Soschner, and Matthias Tarasiewicz and listen about what was going on in the world in 2020 - besides SARS CoV 2.Speaker:Albert Missbichler (https://www.linkedin.com/in/albert-missbichler-3a362931/)Astrid Woollard (https://www.linkedin.com/in/astridwoollard/)Christian Soschner (https://www.linkedin.com/in/christiansoschner/)Elisabeth Pfneisl (https://www.linkedin.com/in/elisabeth-pfneisl-81095163/)Gregory Mannix (https://www.linkedin.com/in/greg-mannix/)Irina Korschineck (https://www.linkedin.com/in/irina-korschineck-35a40289/)Jama Nateqi (https://www.linkedin.com/in/jama-nateqi/)Julia Resch (https://www.linkedin.com/in/julia-resch/)Kimberly Cornfield (https://www.linkedin.com/in/kimberly-cornfield-55383136/)Klara Brandstätter (https://www.linkedin.com/in/klara-brandst%C3%A4tter-b6029491/)Michael Browne (https://www.linkedin.com/in/michael-browne-frsa-5a616138/)Thomas Schirrmann (https://www.linkedin.com/in/thomas-schirrmann-45a64183/)Organizations:Corat Therapeutics (https://www.linkedin.com/company/corat-therapeutics/)CS Life Science Invest (https://lnkd.in/eyhWK7H)Crowdhelix (https://www.linkedin.com/company/crowdhelix/)Falcon Digital Investment (https://www.linkedin.com/company/falcon-digital-investments/about/)Fianostics (https://www.fianostics.at/en/home/)IECT Hermann Hauser (https://www.linkedin.com/company/iect-hermann-hauser)Ingenetix (https://www.ingenetix.com/en/home/)Life Science Nation (https://www.linkedin.com/company/life-science-nation/)RIAT - Research Institute for Future Cryptoeconomics (https://riat.at/)Symptoma (https://www.linkedin.com/company/symptoma/)UCL (https://www.linkedin.com/school/university-college-london/)Vienna Stock Exchange (https://www.linkedin.com/company/wiener-borse-ag/)Yumab (https://www.linkedin.com/company/yumab-gmbh/)Be part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
109 minutes | 5 months ago
#30: How to Patent Digital Business Models
At the beginning of the new millennium, the next technological quantum leap began to emerge, known as the fourth industrial revolution – or Industry 4.0 for short. New technologies permit the development of new business models. In general, a business model describes a company’s business processes to achieve a defined business objective within the context of its social environment. The term sums up visions, ideas, defining features, and design models.In the context of digitization, intellectual property (IP) is becoming an increasingly important element in a company’s strategy to remain competitive by establishing defensible positions. This importance necessitates systematic and value-driven management of IP. In light of the shift from a production-oriented towards a software-driven economy, finding valuable ideas has become a challenging task. The formation of digitalized eco-systems allows new market entrants to compete with established companies easily. Therefore, understanding how intellectual property rights can protect aspects of such digital business models is desirable.Speaker:Prof. Alexander Wurzer (https://www.linkedin.com/in/profalexanderwurzer/)Astrid Woollard (https://www.linkedin.com/in/astridwoollard/)Christian Soschner (https://www.linkedin.com/in/christiansoschner/)Organizations:CS Life Science Invest (https://lnkd.in/eyhWK7H)Falcon Digital Investment (https://www.linkedin.com/company/falcon-digital-investments/about/)IP Business Academy (https://www.linkedin.com/company/ipbusinessacademy/)Be part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
56 minutes | 5 months ago
#29: Ultraleap. Digital Worlds that Feel Human.
One problem in the digital world is: We cannot feel the interaction. Prof. Sriram Subramanian is working on solutions for this problem. He has spun out Ultraleap from the University of Bristol. The company translates the research into products for the digital world.In this episode, I will talk with Prof. Subramanian about real-life applications for his inventions, the importance of touch for well-being, and the potential for the life science industry.Speaker:Christian Soschner (https://www.linkedin.com/in/christiansoschner/)Sriram Subramanian (https://www.linkedin.com/in/srisub/)Organizations:CS Life Science Invest (https://lnkd.in/eyhWK7H)UCL (https://www.linkedin.com/school/university-college-london/)Ultraleap (https://www.linkedin.com/company/ultraleap/)Be part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
54 minutes | 6 months ago
#28: How to Close a 20 million CHF Series B Round During a Pandemic
Let's sit down for a conversation about my favorite topic: Fundraising in the Life Science Industry.How is it to raise significant financing rounds during a pandemic when the research focus is not related to SARS-CoV-2?It is my pleasure to welcome Dr. Daniela Marino, CEO and Co-founder of Cutiss AG.Speaker:Christian Soschner (https://www.linkedin.com/in/christiansoschner/)Daniela Marino (https://www.linkedin.com/in/daniela-marino-3bb35a26/)Organizations:CS Life Science Invest (https://lnkd.in/eyhWK7H)Cutiss AG (https://www.linkedin.com/company/cutiss-ag/)Be part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
59 minutes | 6 months ago
#27: How to Find Your Vision and Passion for Founding a Company
In the last episodes, I have talked with investors and decision-makers of the pharmaceutical industry about the importance of having a vision and passion for the life science company.I want to explore this topic further and ask the life science entrepreneur Christof Goetz to chat with me about finding your vision and passion for your company.Christof is a Serial Entrepreneur with more than 20 years of experience managing complex business, software, and hardware development projects. MyMind is a life science company based in Vienna. MyMinds vision is to help people with neurological impairments to live towards their full brain potential with affordable and easy to use brain training and assessment technology. MyMind currently focuses on Autism Spectrum Disorders (ASD), whether comorbid with Attention Deficit Hyperactivity Disorder (ADHD), Intellectual Disability (low IQ), Epilepsy, and Anxiety. Subsequently, MyMind will extend to other neurological issues such as dementia or stroke recovery.Speaker:Christof Goetz (https://www.linkedin.com/in/christofgoetz/)Christian Soschner (https://www.linkedin.com/in/christiansoschner/)Organizations:CS Life Science Invest (https://lnkd.in/eyhWK7H)My Mind GmbH (https://www.linkedin.com/company/mymindvienna/)Be part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gThe LSG2G Partners Experts in Life ScienceSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
55 minutes | 7 months ago
#26: Science Explained - PCR Tests for Dummies
In this episode, I had the pleasure of talking with two Diagnostics Experts.Irina Korschinek, CEO of Ingenetix and Albert Missbichler, Business Angel specialized in Diagnostics.Do you want to know answers to all or one of the following questions?• What is a PCR test?• Why is it the gold standard for measuring SARS-Cov2 Infections?• What does a positive or negative test result say?• Why do false positives and false negatives exist. Shouldn`t the test have 100% accuracy?• Why do no yes or no answers exist to a viral infection?• What makes diagnostics so complex?Speaker:Albert Missbichler (https://www.linkedin.com/in/albert-missbichler-3a362931/Christian Soschner (https://www.linkedin.com/in/christiansoschner/)Irina Korschinek (https://www.linkedin.com/in/irina-korschineck-35a40289/)Organizations:CS Life Science Invest (https://lnkd.in/eyhWK7H)Ingenetix (https://www.ingenetix.com/en/home/)Fianostics (https://www.fianostics.at/en/home/)Be part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
55 minutes | 7 months ago
#25: What Is the Secret to Successful Tech Transfer?
Did you know that the successful pipeline of one of the most important pharmaceutical companies in the United States started in Europe, and scientists from Prague played a key role? Did you know that profound expertise in turning deep tech life science into a business, scale it, and go public in the US can be found in Prague since the late 80s of the previous century?If you want to know which US pharmaceutical companies pipeline started in Prague, then listen to this Episode Number 25. I am delighted to host an exceptional guest from one of the most beautiful cities in Europe. I will talk with Karel Kubias, from i&i in Prague.Karel studied organic chemistry and photochemistry at TH Merseburg, Germany, and holds an MBA in Healthcare Management (Auburn University program).He gained his broad professional knowledge and skills during his 24 years in various management positions at multinational chemical and pharmaceutical company Merck KGaA. Between 2006 – 2015, Karel worked in executive positions – first as Managing Director of Merck spol. s r.o.. Prague and then as Regional sales director for the region EEMEA (Eastern Europe, Middle East & Africa) of Merck Millipore division, where he acquired further experience on the international level. He now supports i&i Prague as Director for Partnerships and Strategic Alliances.i&i Prague is accelerating the proof-of-concept stage of projects in the fields of Medtech, Diagnostics, and Drug discovery. The company focuses on projects in the discovery, pre-seed, or seed phase, projects with excellent innovative potential, which will benefit from the project-launching experience and networking skills developed by IOCB Tech over the last decade. Furthermore, the financial support provided by i&i Prague should significantly increase the appeal and value of a project for further licensees and/ or investors.Speaker:Christian Soschner (https://www.linkedin.com/in/christiansoschner/)Karel Kubias (https://www.linkedin.com/in/karelkubias/)Organizations:CS Life Science Invest (https://lnkd.in/eyhWK7H)i&i Prague (https://www.linkedin.com/company/iniprague/)IOCB Tech (https://www.linkedin.com/company/iocb-tto-s-r-o-/)IOCB (https://www.linkedin.com/company/iocb-prague/)Be part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gThe LSG2G Partners Experts in Life ScienceSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
55 minutes | 7 months ago
#24: How Young Scientist Are Trained Towards Entrepreneurship in Oxford
Listen to my inspiring conversation with Vassilis Ragoussis about initiatives that support young scientists to become Entrepreneurs. We dived deep into the entrepreneurial Life Science Eco-System in Oxford, Europe, and the United States.If you want to know what the Eco-System in Oxford is doing for young scientist entrepreneurs, this podcast is for you. Learn more about Oxford University Biotech Society and Oxford Foundry.Vassilis is an avid networker and a Ph.D. student at the University of Oxford studying Clinical Medicine. His research requires to analyze large amounts of next-generation sequencing data using bioinformatics and computational analysis. In addition, he critically and objectively assesses his findings, validating any discoveries with functional experiments. During his time at Boston University and Oxford University, he competed at the highest level of rowing, dedicating 30+ hours a week to training and competing, gaining a profound understanding and tremendous respect for teamwork, time management, and team leadership. He has a strong interest in venture capital, life science consulting, and medical device innovations.Speaker:Christian SoschnerVassilis RagoussisOrganizations:CS Life Science Invest (https://lnkd.in/eyhWK7H)Oxford FoundryOxford University Biotech SocietyUniversity of OxfordBe part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gThe LSG2G Partners Experts in Life ScienceSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
59 minutes | 7 months ago
#23: How Is Life These Days for Early-Stage Investors in Europe?
Listen to my conversation with Nicolaj Højer Nielsen about the life of an early-stage investors in Europe.Nicolaj Højer Nielsen is a serial entrepreneur and business angel who has been building startups since 1999. He focuses on high potential startups and has co-founded and invested in thirteen companies, primarily within IT. He has experience securing funding from all possible sources – friends and family, business angels, VC funds, and public funds. His expertise is based on reviewing thousands of different investment opportunities, and he knows the fundraising process from both sides of the table.His latest venture is Copenhagen United, an investment fund focusing on providing capital and mentoring for early-stage software companies.Let`s chat with him about his view on the early-stage investment eco-system in Europe.Speaker:Christian SoschnerNicolaj Højer NielsenCompanies:CS Life Science Invest (https://lnkd.in/eyhWK7H)InProTherBe part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gThe LSG2G Partners Experts in Life ScienceSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
117 minutes | 7 months ago
#22: How Is China Managing the Coronavirus Situation in 2020?
We are in the 7th month of the SARS-CoV-2 Pandemic in Europe.Governments are doing what’s necessary to deal with the situation. More and more governments are initiating strong measures to control the infection rate with SARS-CoV-2. Israel has announced a second lockdown from September 18 for about three weeks.There is a lot of coverage of European measures in the local news. Also, a lot of information is published about actions taken in the United States. I rarely read anything about the situation in Asia. Is life back to normal in Asia? How is the risk assessment of the novel Corona Virus in Asian countries?That‘s why I asked a colleague who lives in Shanghai and is one of the best experts in Life Science and Asia in the world. In this webinar/podcast recording, I will talk with Irénée Robins about these topics. Born in North-Eastern France in 1971, Irénée Robin has been living in China for almost 20 years. Married with three children, genuinely bicultural, he speaks, reads, and writes Mandarin fluently.After ten years in the financial services industry with the BNP Paribas group, Irénée started his life sciences career in 2003 by joining Shanghai Cathay Biotech, where he established his first Sino-foreign joint venture with a major German specialty chemicals conglomerate,leading to the creation of Degussa Cathay Biotechnology in Jining, Shandong Province.From 2006 to 2011, he worked with the Institut Pasteur of Shanghai, an international research venture established by the Chinese Academy of Sciences, the Shanghai municipal government, and Institut Pasteur. Under his tenure, the institute grew from 40 to 240 researchers, with numerous drug/vaccine discovery programs against life-threatening infectious diseases such as HFMD, HCV, and malaria. His efforts were directed at increasing the institute’s financial resources, notably via expanding CSR programs with multinational corporations and successfully applying to European and international grants.In 2012, as a Senior Representative for the Biotechnology Innovation Organization (BIO), he organized the “BIO Convention in China” in Shanghai.From 2013 to early 2019, he was the Chief Marketing Officer for Shanghai Newsummit Biopharma, a subsidiary of Shenzhen-listed Zhejiang Yatai Pharmaceuticals (SHE:002370). During those six years, he attracted more than 30 Western companies onto the Chinese market through a vast array of transaction types, from in-licensing to co-development, distribution, and service agreements. He also established 4 Sino-foreign joint ventures in 4 different Chinese cities, including China’s most advanced molecular pathology and next-gen cancer diagnostics lab (Shanghai German JV partner) and a first-in-class IVD development venture based on patients’ immune status markers, the use of NGS platforms, and targeted data mining/deep learning algorithms (Guangzhou – French JV partner).Speaker:Christian Soschner (https://www.linkedin.com/in/christiansoschner/)Irénée Robin (https://www.linkedin.com/in/ireneerobin/)Companies:CS Life Science Invest (https://www.cslifescienceinvest.com/)VVR Medical (https://www.linkedin.com/company/vvr-international/)Be part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gThe LSG2G Partners Experts in Life ScienceSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
53 minutes | 8 months ago
#21: How to Partner with Big Pharma?
Do you want to know how to approach Pharma?Do you want to learn what information is needed to partner a life science project with Pharma?And how long the process takes?Then this podcast is for you.Listen to the expertise of Natalia Novac, Director of Emerging Technologies and Innovation, Eli Lilly.Natalia has profound experience in strategy, corporate, and business development. She had leading roles at Merck and now Eli Lilly.Speaker:Christian Soschner (https://www.linkedin.com/in/christiansoschner/)Natalia Novac (https://www.linkedin.com/in/natalia-novac-a3aa7131/)Companies:Eli Lilly (https://www.linkedin.com/company/eli-lilly-and-company/)CS Life Science Invest (https://www.cslifescienceinvest.com/)Be part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gThe LSG2G Partners Experts in Life ScienceSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
42 minutes | 8 months ago
#20: How to close a 40 million Euro financing round in less than 8 weeks
In light of the pandemic, the Life Science Industry is changing. One of the positive developments: The industry is moving faster. The necessity of developing diagnostics, therapeutics, and vaccines against this novel viral threat quickly generates a steep learning curve for all of us.In this episode, I am talking with Peter Llewellyn-Davies, CEO of Apeiron Biologics, how he and his team have set up a clinical phase 2 trial and a 40 million Euro financing round in less than eight weeks.Speaker:Christian Soschner (https://www.linkedin.com/in/christiansoschner/)Peter Llewellyn-Davies (https://www.linkedin.com/in/peterld/)Companies:Apeiron Biologics (https://www.linkedin.com/company/apeiron-biologics/)CS Life Science Invest (https://www.cslifescienceinvest.com/)Be part of our Network:Subscribe here: https://mailchi.mp/e2467061ef75/lsg2gThe LSG2G Partners Experts in Life ScienceSupport the show (https://www.lifescienceget2gether.com/registration-membersclub/)
Terms of Service
Do Not Sell My Personal Information
© Stitcher 2021